Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CDX-585

Bispecific antibody · Immune activation, directed at programmed cell death protein 1 (PDCD1) and immunoglobulin-like transcript 4 (LILRB2) · developed by Celldex Therapeutics

Phase 1 Most advanced trial (none active)

CLDX Developer

1 Registered trials

What is CDX-585?

CDX-585 is a humanized IgG1 kappa bispecific antibody that binds both PD-1 and ILT4 (LILRB2), blocking PD-1 engagement by its ligands and ILT4 signaling by MHC class I molecules. Dual checkpoint blockade is intended to enhance T-cell activation and cytotoxic T-lymphocyte killing of tumor cells. It is being studied in multiple solid tumors, including non-small cell lung, gastric, head and neck, ovarian, colorectal, and pancreatic cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: programmed cell death protein 1 (PDCD1), immunoglobulin-like transcript 4 (LILRB2), programmed cell death 1 ligand 1 (CD274) (binding partner it blocks)
Mechanism: Immune activation, directed at programmed cell death protein 1 (PDCD1) and immunoglobulin-like transcript 4 (LILRB2)
Pathways: T-cell activation, cytotoxic T-lymphocyte-mediated tumor cell lysis, pro-inflammatory cytokine expression (GM-CSF, TNF-alpha)
Therapy area: Oncology
Developer: Celldex Therapeutics (CLDX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05788484	Phase 1	Non-small Cell Lung Cancer	Completed	CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder Urothelial CarcinomaCholangiocarcinomaColorectal CancerEsophageal CancerFallopian Tube CancerGastric CancerHead and Neck CancerHepatic CancerNon-small Cell Lung CancerOther Solid TumorsOvarian CancerPancreatic CancerPrimary Peritoneal CarcinomaRenal Cell Carcinoma

Other drugs acting on PDCD1 / LILRB2

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CHS-1000 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2

More from Celldex Therapeutics

Barzolvolimab Phase 3 CDX 0158 Phase 1 CDX-014 Phase 1 CDX-1140 Phase 2 CDX-1307 Phase 2 CDX-301 Phase 2 CDX-3379 Phase 2 CDX-527 Phase 1 CDX-622 Phase 1 Glembatumumab Vedotin Phase 2 Keyhole Limpet Hemocyanin Phase 2 Rindopepimut Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.

Follow CLDX, the company behind CDX-585

See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLDX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z